Sales increase of 3.3 million compared to last year period – EBIT declines to 1.29 million Euros – Gratifying growth in the Middle East and in Asia
Jena, August 22nd, 2012 – biolitec AG (ISIN DE0005213409), Jena, listed on the Prime Standard of the Frankfurt Stock Exchange, achieved group sales of 29.4 million Euros in the first three quarters of the 2011/12 fiscal year. Thus, sales increased by approximately 3.3 million Euros compared to the same period in the previous fiscal year. The growth in sales is attributable to the steadily rising demand for biolitec treatments; for example, for the benign prostate hyperplasia (LIFE?), the endoluminal laser treatment for veins (ELVeS?) and the new HeLP? (Haemorrhoid Laser Procedure) treatment for the atrophy of haemorrhoidal arteries.
Expenses relating to Research & Development for the first three quarters of the 2011/12 fiscal year for an amount of 3.18 million Euros (approximately 10.8% of sales) reached the previous year“s level. The sales and marketing expensed have increased to 9.13 million Euros (compared to 8.04 million Euros in the same period of the previous year).
The gross profit of 18.56 million Euros has remained at the level of the previous year (previous year: 18.59 million Euros) and the Earnings Before Interest and Tax (EBIT) declined to 1.29 million Euros (previous year: 1.49 million Euros).
Significant revenues of biolitec AG were achieved in Europe and North America. With 10.8 million Euros, the sales in North America were 14% higher than those in the previous fiscal year (9.4 million Euros). The sales in Europe reached 11.9 million Euros (previous fiscal year: 11.8 million Euros). biolitec AG“s subsidiaries abroad, particularly in the Middle East and in Asia, delivered sales figures that showed gratifying growth rates of 37% (reaching 6.7 million Euros) as compared to the first three quarters of the previous year. biolitec“s medium-term goal is to increase the share of group revenue in these markets to one-third of sales.
The sales figure for the Meditec segment was 28.3 million Euros in the first three quarters, in the pharmaceuticals segment sales increased to nearly 1.1 million Euros.
biolitec has decided to publish its results for the first three quarters of 2011/12 even though the annual statement of accounts for 2010/11 has not yet been audited (the unaudited sales figure for which was 35.24 million Euros). The tentative sales figures for the 2011/12 fiscal year for the biolitec group are pegged at 40.27 million Euros.
In the meantime, biolitec has decided to relocate its registered office to Austria. In the course of the merger, the biolitec share shall be exchanged into new shares to the Entry Standard. Thus, continuous trading of the shares in the quality segment Entry Standard of the Frankfurt Stock Exchange shall be ensured for the shareholders. Dr. Neuberger, CEO of biolitec AG, states: „The listing in the Entry Standard of the Frankfurt Stock Exchange requires less regulatory effort and saves costs for the company.“
To combine the transfer to Vienna with the already announced changeover to the Entry Standard, BioMed Technology Investment Holding as major shareholder with slightly more than 75% of the voting rights in biolitec AG has already announced to vote for the merger with biolitec AG“s Austrian subsidiary at the Extraordinary General Meeting of biolitec AG. The acceptance of a corresponding request is therefore ensured.
For the coming fiscal year 2012/13, biolitec expects growth to be sustained.
The information does not constitute an offer of or an invitation by or on behalf of biolitec AG or any of its subsidiaries to subscribe for or purchase securities of biolitec AG or any of its subsidiaries.
In particular, the information contained does not constitute an offer of securities for sale or solicitation of an offer to buy securities in the United States of America.
biolitec® AG is one of the leading companies worldwide in the field of medical laser treatments und the only provider that possesses all relevant core competencies – photosensitizers, laser devices and optical fibres – in the field of photodynamic therapy (PDT). Besides the laser treatment of cancer with Foscan®, biolitec® primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS Radial? (Endo Laser Vein System) the laser system is most often used worldwide for the treatment of varicose veins. Ceralas® HPD laser therapy enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics, gynaecology as well as ophtalmology also belong to the business field of biolitec®. biolitec® is listed in the Prime Standard (ISIN DE0005213409). Further information at www.biolitec.de.
Kontakt:
biolitec AG
Jörn Gleisner
Otto-Schott-Straße 15
07745 Jena
+49 (0) 69/959083-20
info@biolitec.de
http://www.biolitec.de
Pressekontakt:
fr financial relations gmbh
Jörn Gleisner
Gutleutstr. 75
60329 Frankfurt
+49 (0) 69 / 959083-20
joern.gleisner@biolitec.com
http://www.biolitec.de